Subscribe

Modern Dental Group Limited (3600.HK)

HKD7.70 +0.46 (+6.35%)
HK HKSE Healthcare Medical - Instruments & Supplies
Address CEO Tower
Kowloon, HK
CEO Yik Long Chan
Website moderndentalgp.com
IPO 2015-12-15
ISIN KYG618201092

Explore sections of this company profile

Description

Modern Dental Group Limited, an investment holding entity, is a prominent provider specializing in the manufacturing and worldwide distribution of dental prosthetic devices. Its extensive operations reach various international markets, including Europe, Greater China, North America, and Australia. The company's offerings are structured across three primary segments. The Fixed Prosthetic Devices division provides restorative dental solutions such as crowns, bridges, and implants. Concurrently, the Removable Prosthetic Devices segment is dedicated to producing both full and partial dentures, which can include metal frameworks or be entirely metal-free. Furthermore, its "Others" segment encompasses a diverse range of products like orthodontic appliances, sports guards, anti-snoring devices, raw materials, and various dental equipment. This segment also extends to offering professional services, including educational events and seminars. Modern Dental Group serves a broad clientele comprising dentists, dental clinics, hospitals, distributors, and other professional customers. Its comprehensive product line is marketed under numerous recognized brands, such as Permadental & Semperdent, Schmidt, Apex Digital Dental, Elysee, Labocast, Modern Dental Laboratory, Yangzhijing, Southern Cross Dental, Andent, Modern Dental USA, Sundance Dental, Quantum Dental, TrioClear, and Digitek Dental. The company was established in 1986 and is headquartered in Kowloon, Hong Kong.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD7.70 +0.46 (+6.35%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
646.2K
Beta
0.83
Float Shares
299.00M
Free Float %
32.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+3.21% +0.17% -3.67% -1.37% +13.11% +8.44% +44.14% +142.86% -29.25% +59.23% +43.07%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
7.70
DCF (Unlevered) 8.59 +11.5%
DCF (Levered) 8.69 +12.9%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2025-12 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
5.47
Safe zone
Piotroski F-Score
9 / 9
Strong
MOAT Score
8 / 10
Strong MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers ★ Strong MOAT
  • ✓
    Revenue growth Medical - Instruments & Supplies: +7.9%
    +11.1% ★ Q4'25: +21.1% (vs Q4'23)
  • ✓
    EPS growth Medical - Instruments & Supplies: +16.3%
    +48.8% ★ Q4'25: +65.0% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%
    +14.1% ★ Q4'25: +22.6% (vs Q4'23)
  • ✓
    EBIT margin Medical - Instruments & Supplies: +13.5%
    +20.2% ★ Q4'25: +20.6% (vs Q4'23)
  • ✓
    ROIC Medical - Instruments & Supplies: +6.0%
    +18.8% ★ Q4'25: +38.9% (vs Q4'23)
  • ✓
    Share dilution Medical - Instruments & Supplies: +0.1%
    -0.9% ★ Q4'25: -1.4% (vs Q4'23)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×
    0.77× Q4'25: 0.37× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.04) × ERP
WACC = 89% × Ke + 11% × Kd (5.3%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 8.59 Current price: 7.70
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana.
Revenue
1.42B
est: 1.40B (+1.0%)
1.64B
est: 1.62B (+1.5%)
2.18B
est: 2.41B (-9.4%)
2.32B
est: 2.36B (-2.1%)
2.40B
est: 2.58B (-7.0%)
2.19B
est: 2.21B (-1.0%)
2.96B
est: 2.94B (+0.5%)
2.83B
est: 2.83B (+0.1%)
3.17B
est: 3.27B (-3.1%)
3.36B
est: 3.46B (-2.8%)
3.74B
est: 3.75B (-0.4%)
4.13B
4.13B – 4.13B
+10.2% YoY
4.56B
4.56B – 4.56B
+10.4% YoY
EBITDA
248.94M
est: 264.78M (-6.0%)
294.88M
est: 187.52M (+57.2%)
300.77M
est: 253.79M (+18.5%)
268.10M
est: 446.48M (-40.0%)
393.32M
est: 487.09M (-19.3%)
295.21M
est: 254.01M (+16.2%)
627.01M
est: 555.27M (+12.9%)
464.09M
est: 323.41M (+43.5%)
696.64M
est: 678.49M (+2.7%)
719.12M
est: 717.61M (+0.2%)
848.79M
est: 777.53M (+9.2%)
856.73M
856.73M – 856.73M
+10.2% YoY
945.47M
945.47M – 945.47M
+10.4% YoY
EBIT
184.74M
est: 194.94M (-5.2%)
225.01M
est: 212.79M (+5.7%)
211.17M
est: 237.93M (-11.2%)
173.29M
est: 328.72M (-47.3%)
235.73M
est: 358.62M (-34.3%)
159.46M
est: 238.14M (-33.0%)
493.21M
est: 408.82M (+20.6%)
314.48M
est: 303.20M (+3.7%)
550.33M
est: 539.60M (+2.0%)
578.46M
est: 570.71M (+1.4%)
754.89M
est: 618.37M (+22.1%)
681.36M
681.36M – 681.36M
+10.2% YoY
751.94M
751.94M – 751.94M
+10.4% YoY
Net Income
81.96M
est: 330.43M (-75.2%)
101.48M
est: 98.60M (+2.9%)
155.37M
est: 133.01M (+16.8%)
85.39M
est: 189.03M (-54.8%)
161.56M
est: 207.93M (-22.3%)
107.76M
est: 133.13M (-19.1%)
360.83M
est: 368.60M (-2.1%)
220.46M
est: 331.81M (-33.6%)
404.10M
est: 401.99M (+0.5%)
408.00M
est: 449.72M (-9.3%)
596.97M
est: 543.42M (+9.9%)
618.37M
618.37M – 618.37M
+13.8% YoY
693.32M
693.32M – 693.32M
+12.1% YoY
SGA
582.22M
est: 513.76M (+13.3%)
655.05M
est: 700.37M (-6.5%)
850.76M
est: 897.53M (-5.2%)
905.70M
est: 866.33M (+4.5%)
902.63M
est: 945.13M (-4.5%)
800.79M
est: 898.32M (-10.9%)
1.06B
est: 1.07B (-0.8%)
1.08B
est: 1.14B (-5.8%)
1.16B
est: 1.19B (-2.5%)
1.22B
est: 1.26B (-3.3%)
1.32B
est: 1.37B (-3.2%)
1.50B
1.50B – 1.50B
+10.2% YoY
1.66B
1.66B – 1.66B
+10.4% YoY
EPS
0.10
est: 0.35 (-71.6%)
0.10
est: 0.17 (-39.4%)
0.16
est: 0.16 (+3.2%)
0.09
est: 0.20 (-57.2%)
0.16
est: 0.22 (-27.3%)
0.11
est: 0.12 (-8.3%)
0.38
est: 0.39 (-2.6%)
0.23
est: 0.23 (+1.8%)
0.42
est: 0.43 (-2.1%)
0.43
est: 0.48 (-10.4%)
0.64
est: 0.58 (+10.3%)
0.66
0.66 – 0.66
+13.8% YoY
0.74
0.74 – 0.74
+12.1% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A 4/5 4/5 5/5 5/5 2/5 3/5 4/5
2026-05-28 A 4/5 4/5 5/5 5/5 2/5 3/5 4/5
2026-05-27 A 4/5 4/5 5/5 5/5 2/5 3/5 4/5
2026-05-26 A 4/5 4/5 5/5 5/5 2/5 3/5 4/5
2026-05-22 A 4/5 4/5 5/5 5/5 2/5 3/5 4/5
2026-05-21 A 4/5 4/5 5/5 5/5 2/5 3/5 4/5
2026-05-20 A 4/5 4/5 5/5 5/5 2/5 3/5 4/5
2026-05-19 A 4/5 4/5 5/5 5/5 2/5 3/5 4/5
2026-05-18 A 4/5 4/5 5/5 5/5 2/5 3/5 4/5
2026-05-15 A 4/5 4/5 5/5 5/5 2/5 3/5 4/5
2026-05-14 A 4/5 4/5 5/5 5/5 2/5 3/5 4/5
2026-05-13 A 4/5 4/5 5/5 5/5 2/5 3/5 4/5
2026-05-12 A 4/5 4/5 5/5 5/5 2/5 3/5 4/5
2026-05-11 A 4/5 4/5 5/5 5/5 2/5 3/5 4/5
2026-05-08 A+ 4/5 4/5 5/5 5/5 2/5 4/5 4/5
2026-05-07 A+ 4/5 4/5 5/5 5/5 2/5 4/5 4/5
2026-05-06 A+ 4/5 4/5 5/5 5/5 2/5 4/5 4/5
2026-05-05 A+ 4/5 4/5 5/5 5/5 2/5 4/5 4/5
2026-05-04 A+ 4/5 4/5 5/5 5/5 2/5 4/5 4/5
2026-04-30 A+ 4/5 4/5 5/5 5/5 2/5 4/5 4/5
2026-04-29 A+ 4/5 4/5 5/5 5/5 2/5 4/5 4/5
2026-04-28 A+ 4/5 4/5 5/5 5/5 2/5 4/5 4/5
2026-04-27 A+ 4/5 4/5 5/5 5/5 2/5 4/5 4/5
2026-04-24 A 4/5 4/5 4/5 5/5 2/5 4/5 4/5
2026-04-23 A 4/5 4/5 4/5 5/5 2/5 3/5 4/5
2026-04-22 A 4/5 4/5 4/5 5/5 2/5 3/5 4/5
2026-04-21 A- 4/5 4/5 4/5 5/5 1/5 3/5 4/5
2026-04-20 A- 4/5 4/5 4/5 5/5 1/5 3/5 4/5
2026-04-17 A- 4/5 4/5 4/5 5/5 1/5 3/5 4/5
2026-04-16 A- 4/5 4/5 4/5 5/5 1/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
981.97M
OE per share TTM
1.04
Owner's Yield
18.17%
Maintenance CapEx ratio
10.04%
Maint CapEx / Avg PPE
28.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 10 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares International Small-Cap Equity Factor ETF ISCF 0.04% 255.3K 0.24%
2 State Street SPDR S&P International Small Cap ETF GWX 0.02% 183.9K 0.40%
3 Dimensional - International Small Cap ETF DFIS 0.01% 366.4K 0.39%
4 Avantis Responsible International Equity ETF AVSD 0.00% 13.3K 0.23%
5 Dimensional - International Core Equity 2 ETF DFIC 0.00% 354.1K 0.22%
6 State Street SPDR Portfolio Developed World ex-US ETF SPDW 0.00% 665.9K 0.03%
7 Dimensional World ex U.S. Core Equity 2 ETF DFAX 0.00% 195.5K 0.28%
8 Dimensional - International Vector Equity ETF DXIV 0.00% 892.29 0.53%
9 Avantis International Equity ETF AVDE 0.00% 37.2K 0.23%
10 Dimensional - International Core Equity Market ETF DFAI 0.00% — 0.18%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
106.2K
Shares Outstanding
934.85M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Yik Long Chan Chief Executive Officer & Executive Chairman 9M —
Yik Yu Chan Chief Marketing Officer & Executive Director 5M female
Chi Yuen Chan Executive Director 5M male
Kwun Pan Chan Executive Director 5M male
Ngai Kit Kwan Chief Financial Officer & Company Secretary — male
Gregory Scialom President of Labocast SAS — male
August Wilhelm Torsten Schwafert Chief Executive Officer of Modern Dental Europe BV — male
Tara Cullen Chief Executive Officer of Modern Dental Pacific — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Instruments & Supplies